Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
2013586 citationsAnn‐Lii Cheng, Yoon‐Koo Kang et al.Journal of Clinical Oncologyprofile →
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late)
cites ·
hero ref
This map shows the geographic impact of Guido Poggi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Guido Poggi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Guido Poggi more than expected).
This network shows the impact of papers produced by Guido Poggi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Guido Poggi. The network helps show where Guido Poggi may publish in the future.
Co-authorship network of co-authors of Guido Poggi
This figure shows the co-authorship network connecting the top 25 collaborators of Guido Poggi.
A scholar is included among the top collaborators of Guido Poggi based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Guido Poggi. Guido Poggi is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Cheng, Ann‐Lii, Yoon‐Koo Kang, Deng‐Yn Lin, et al.. (2013). Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial. Journal of Clinical Oncology. 31(32). 4067–4075.586 indexed citations breakdown →
4.
Poggi, Guido, et al.. (2013). Unusual case of ascites. International Journal of Case Reports and Images. 4(1). 32–32.
Poggi, Guido, Benedetta Montagna, Fabio Melchiorre, et al.. (2011). Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma.. PubMed. 31(11). 3927–33.8 indexed citations
Poggi, Guido, Alberto Riccardi, Stefano Tonini, et al.. (2010). Complications of image-guided transcatheter hepatic chemoembolization of primary and secondary tumours of the liver.. PubMed. 30(12). 5159–64.21 indexed citations
Candura, Stefano M., et al.. (2008). Malignant mesothelioma of the tunica vaginalis testis in a petrochemical worker exposed to asbestos.. PubMed. 28(2B). 1365–8.9 indexed citations
16.
Poggi, Guido, Alberto Riccardi, Pietro Quaretti, et al.. (2007). Complications of percutaneous radiofrequency thermal ablation of primary and secondary lesions of the liver.. PubMed. 27(4C). 2911–6.21 indexed citations
17.
Poggi, Guido, Carlo Gatti, Mario Melazzini, et al.. (2004). Percutaneous ultrasound-guided radiofrequency thermal ablation of malignant osteolyses.. PubMed. 23(6D). 4977–83.16 indexed citations
18.
Poggi, Guido, Carlo Gatti, Cristina Teragni, Angelo Delmonte, & Giovanni Di Bernardo. (2004). Radiofrequency ablation combined with percutaneous ethanol injection in the treatment of hepatocellular carcinoma and portal vein neoplastic thrombosis.. PubMed. 24(4). 2419–21.12 indexed citations
19.
Poggi, Guido, et al.. (2001). Percutaneous US-guided radiofrequency ablation of hepatocellular carcinomas: results in 15 patients.. PubMed. 21(1B). 739–42.14 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.